Apterna

Transforming drug delivery with precision RNA aptamers

About us

Apterna is a pre-clinical biotechnology company developing chemically synthesised RNA aptamers that bind to target molecules with outstanding specificity and affinity.

We are developing internalising RNA aptamers that enable targeted delivery of various payloads including RNA, toxins, enzymes, chemotherapy agents, photodynamic molecules, radionuclides and nanocarriers.

The Company was founded by Professors John Rossi and Nagy Habib in 2011.

Further reading

Yoon, S et al. Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth. Molecular Therapy - Nucleic Acids, Vol 6, pp 80-88

Zhou, J et al. Current progress of RNA aptamer-based therapeutics. Front Genet. 2012 Nov 2;3:234

Keefe, A et al. Aptamers as therapeutics. Nat Rev Drug Discov. 2010 Jul;9(7):537-50